Name: Clinuvel Pharmaceuticals (CUV) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

CUV

Pharmaceuticals, Biotechnology & Life Sciences

Clinuvel Pharmaceuticals

Short interest: 8.93%; +0.62 pp 30d; as of 12 Oct 2026
Reported shorts: 4.5M
Shares on issue: 50.487M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Ltd. is a pioneering Australian company specializing in the development of innovative treatments for UV and light-related skin disorders. Their flagship product, SCENESSE®, is the first systemic photoprotective drug approved for preventing phototoxicity in patients with erythropoietic protoporphyria. The company leverages its expertise in photomedicine and melanocortin peptides to address unmet medical needs globally.

Company profile →

Clinuvel Pharmaceuticals (ASX:CUV) has 8.93% of its shares on issue reported as short positions as of 12 Oct 2026, or about 4,509,827 shares. Over the past 30 days that figure has risen 0.62 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 10.04% in August 2020. CUV is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 42, 2026.

Strategy fit

How each stock picker strategy reads CUV today

Zanger BreakoutWatchScore 7rank 1790 of 1918
CAN SLIMWatchScore 7rank 1377 of 1540
Minervini Trend TemplateWatchScore 7rank 1479 of 1695
Crowded-Short BreakoutSetupScore 41rank 39 of 1453
Quality compoundersWatchScore 48rank 135 of 1668

Prices to 16 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

CUV fundamentals

In the year to 30 Jun 2026, Clinuvel Pharmaceuticals (ASX:CUV) recorded revenue of A$94.0M and net profit after tax of A$33.9M. A year earlier it recorded revenue of A$95.0M and net profit after tax of A$36.2M. Year-on-year growth: revenue −1.0% (FY), EPS −7.0% (FY). Net margin 36.1%, return on equity 13.2% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →